GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: depemokimab-ulaa | Exdensur® | GSK-3511294 | GSK3511294
depemokimab is an approved drug
Compound class:
Antibody
Comment: Depemokimab (GSK-3511294) is a humanized IgG1κ monoclonal; antibody that targets interleukin 5 (IL-5). It binds to the same epitope as, but with higher affinity mepolizumab [4].
|
| No information available. |
Summary of Clinical Use ![]() |
| Depemokimab was approved by the UK MHRA and US FDA in December 2025, as an add-on maintenance therapy in the treatment of severe eosinophilic asthma [1]. |